TransCode Therapeutics Inc
RNAZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.19M
Close$
$25.83
642.2% upside
Current Fair Value
642.2% upsideUndervalued by 642.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.19 Million |
|---|---|
| Enterprise Value | $-7,662,843,419.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-52.59 |
| Beta | 1.24 |
| Outstanding Shares | 916,968 |
Return
| Return on Equity | 226.14% |
|---|---|
| Return on Assets | -41.47% |
| Return on Invested Capital | 0.01% |
Valuation & Multiples
| P/E Ratio | -0.08 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -468.34 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.09 |
| Debt to Equity | -0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.37%▲ 2.80% |
|---|---|
| Total Invested | $265,677▲ 904.60% |
| Investors Holding | 7▲ 2.00% |
ESG Score
No data
About TransCode Therapeutics Inc
2,021 employees